Class Action Involving Cancer Drug Monopoly Pursued to Resolution
Lash & Goldberg LLP served as co-counsel for its named plaintiff client in this federal antitrust class action against Bristol-Myers alleging the unlawful monopolization of the national market for paclitaxel, a cancer drug sold under the brand name Taxol.
The antitrust scheme included Bristol-Myers’ alleged conduct to block generic competition in the United States. The United States District Court for the District of Columbia approved a settlement in favor of the class of direct purchasers in the amount of $65,815,000. The litigation and settlement gave rise to other subsequent actions brought by various State Attorney Generals’ offices and the Federal Trade Commission.